Effect of Nervus Cutaneous Femoris Lateralis-Blockade on Moderate Pain Responders After Total Hip Arthroplasty

• Status: Completed
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The patients will be included the 1. or 2. day after surgery. All THA patients will be screened. Those reporting VAS > 40 during active 30 degrees hip flexion will be asked to participate.

Included patients will receive 2xNCFL (singleshot) first placebo (8 ml saline) and then ropivacaine (8 ml ropivacaine 7,5mg/ml) or the other way around (randomized). There will be 45 minutes between the two blockades. The blockades will be ultrasound guided.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daniel Hägi-Pedersen
• Treatments: Ropivacaine

Criteria

Inclusion Criteria:

• THA within 48 hours and VAS>40 during active 30 degrees hip flexion despite conventional pain medication.

• informed consent

• ASA 1-3

• BMI 18-40

Exclusion Criteria:

• Unable to communicate in danish

• Allergic reactions toward drugs used

• Abuse of alcohol/drugs

• Unable to cooperate

• Pregnant women